Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Moleculin Biotech ( (MBRX) ).
On January 27, 2025, Moleculin Biotech announced that its CEO, Walter Klemp, participated in a Virtual Investor ‘What This Means’ segment. During the event, Klemp shared updates on the MIRACLE trial, a Phase 3 study evaluating Annamycin for treating relapsed or refractory acute myeloid leukemia. This trial is a significant step for Moleculin as it expands globally, with sites in the US, Europe, and the Middle East, and reflects advancements in AML treatment. Moleculin’s progress in developing Annamycin and other drug candidates could enhance its position in the pharmaceutical industry, with potential implications for regulatory approval and stakeholder investment.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. The company’s lead program, Annamycin, aims to treat relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases without the cardiotoxicity of traditional anthracyclines. Moleculin is also working on other drug candidates targeting brain tumors, pancreatic cancers, and pathogenic viruses.
YTD Price Performance: -3.95%
Average Trading Volume: 55,759
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.42M
For detailed information about MBRX stock, go to TipRanks’ Stock Analysis page.
